Generic Opportunities Arising for the Blockbuster Antihypertensive, Diovan® (Valsartan)

Share Article

GenericsWeb, a leader in established pharmaceutical patent searching and analysis, recently published an article that analysed the patent landscape surrounding Novartis’ Diovan® (Valsartan) and the subsequent opportunities available to launch a generic equivalent.

It was seen from GenericsWeb’s analysis that due to the impending expiry of the US patent protecting the Valsartan active ingredient in September 2012 and the relatively low level of technology required to circumvent the existing “dry-granulation” formulation, many generic companies have been quick to pounce on this opportunity, having already received tentative approvals by the FDA and one could expect to see a generic equivalent hit the shelves of US pharmacies late next year.

The article suggests that perhaps due to the inevitable generic competition that is expected to eat into the market share of the high-blood pressure therapies market that Novartis currently maintains a stranglehold of, a push towards prescription of Valsartan with other fixed-dose combinations by the innovator could be the most effective way of extending the life-cycle of this product.

The article also noted that Novartis appears to have been very proactive in extending the protection of Valsartan in combination with Amlodipine (with or without HCTZ), although there appears to be a significant amount of contention surrounding this formulation, evidenced by large amounts of opposition filed by generic competitors in the European territory, the results of which will decide the longevity of this combination on the market.

Valsartan, an angiotensin II receptor antagonist, indicated for the treatment of hypertension, congestive heart failure and post Myocardial-Infarction, is available as film-coated tablets.

You can read the full article here:

GenericsWeb, the leader in pharmaceutical patent searching and analysis holds an impeccable track record in providing quality patent information, allowing numerous pharmaceutical companies to successfully navigate intellectual property hazards. GenericsWeb is headquartered in Sydney, Australia, with offices in North America and Europe. All staffs are highly skilled and experienced and have extensive experience in pharmaceutical sciences and patent searching. For more information, visit the company's web site at


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Yoann Bretonnet
+61 2 9262 7696
Email >
Visit website